The Raf family of protein kinases are key signaling intermediates, acting as a central link between the membrane-bound Ras GTPases and the downstream kinases MEK and ERK. Raf kinase regulation is well-known for its complexity but only recently has it been realized that many of the mechanisms involved in Raf regulation also modulate Raf dimerization, now acknowledged to be a required step for Raf signaling in multiple cellular contexts. Recent studies have shown that Raf dimerization is necessary for normal Ras-dependent Raf kinase activation and contributes to the pathogenic function of disease-associated mutant Raf proteins with all but high intrinsic kinase activity. Raf dimerization has also been found to alter therapeutic responses and disease progression in patients treated with ATP-competitive Raf inhibitors as well as certain other kinase-targeted drugs. This demonstration of clinical significance has stimulated the recent development of biosensor assays that can monitor inhibitor-induced Raf dimerization as well as studies demonstrating the therapeutic potential of blocking Raf dimerization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976976PMC
http://dx.doi.org/10.4161/sgtp.26117DOI Listing

Publication Analysis

Top Keywords

raf dimerization
24
raf
13
raf kinase
8
dimerization
5
dimerization cell
4
cell signaling
4
signaling raf
4
raf family
4
family protein
4
protein kinases
4

Similar Publications

Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery.

Biosensors (Basel)

November 2024

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.

Recent advances in drug discovery have established biosensors as indispensable tools, particularly valued for their precision, sensitivity, and real-time monitoring capabilities. The review begins with a brief overview of cancer drug discovery, underscoring the pivotal role of biosensors in advancing cancer research. Various types of biosensors employed in cancer drug discovery are then explored, with particular emphasis on fluorescence- and bioluminescence-based technologies such as FRET, TR-FRET, BRET, NanoBRET, and NanoBiT.

View Article and Find Full Text PDF

Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases.

Cancers (Basel)

December 2024

Team Laboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium.

Background: There are no active treatment options for patients with progressive melanoma brain metastases (MBM) failing immune checkpoint blockade (ICB) and BRAF/MEK inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-kinase inhibitor (incl. RAF-dimer inhibition), can overcome adaptive resistance to BRAF/MEKi in preclinical models.

View Article and Find Full Text PDF

A comprehensive review of targeting RAF kinase in cancer.

Eur J Pharmacol

January 2025

Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh. Electronic address:

Article Synopsis
  • RAF kinases, especially BRAF, are essential in the MAPK/ERK signaling pathway, influencing cell growth and survival; mutations in the BRAF gene can lead to cancer, particularly melanoma with the BRAF-V600E mutation.
  • Targeted therapies like vemurafenib and dabrafenib have shown significant success in treating BRAF-V600E-mutant melanomas and some other cancers, improving patient outcomes despite their challenges.
  • Therapeutic resistance is a major issue due to mechanisms like RAF dimerization and pathway reactivation, prompting research into combination therapies and new RAF inhibitors to enhance treatment effectiveness and specificity.
View Article and Find Full Text PDF

Two hearts beat as one: the debate over RAS dimers continues.

Trends Biochem Sci

November 2024

NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address:

Article Synopsis
  • - A recent report by Yun et al. focuses on detecting RAS dimers through intact mass spectrometry.
  • - The study explores how membrane lipids, nucleotide state, and binding partners influence the formation of RAS dimers.
  • - This research enhances our understanding of the biochemical environment impacting RAS protein interactions and their implications in cellular functions.
View Article and Find Full Text PDF

Raf protein kinases act as Ras-GTP sensing components of the ERK signal transduction pathway in animal cells, influencing cell proliferation, differentiation, and survival. In humans, somatic and germline mutations in the genes BRAF and RAF1 are associated with malignancies and developmental disorders. Recent studies shed light on the structure of activated Raf, a heterotetramer consisting of Raf and 14-3-3 dimers, and raised the possibility that a Raf C-terminal distal tail segment (DTS) regulates activation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!